Tylenol Autism Lawsuit 2026 | Pregnancy Use, Claims, Evidence and Eligibility

The Tylenol Autism Lawsuit focuses on claims that prenatal use of acetaminophen, the active ingredient in Tylenol, may be linked to a higher risk of autism, ADHD, and other neurodevelopmental conditions in children. Families allege that manufacturers failed to adequately warn expectant mothers about these potential risks, potentially leading to preventable harm.

The lawsuits combine scientific research, expert testimony, and legal review to determine whether stronger warnings or labeling could have helped parents make informed decisions. While evidence is still evolving and does not prove causation, the litigation highlights questions of safety, corporate responsibility, and the rights of affected families.

On this page, you will learn about what the lawsuit is about, the alleged health risks, who is involved, the evidence presented, eligibility to file a claim, and the potential legal outcomes.

What Is the Tylenol Autism Lawsuit About?

The Tylenol autism lawsuit centers on claims that the makers and sellers of Tylenol and other acetaminophen based pain relievers failed to warn consumers about potential risks associated with using the drug during pregnancy. Plaintiffs allege that prenatal exposure to acetaminophen may increase the risk of children developing autism spectrum disorder or attention deficit hyperactivity disorder. The lawsuits argue that manufacturers knew or should have known about these potential risks but continued to market the drug as safe for use during pregnancy without adequate warnings.

The claims are largely based on scientific studies that have reported an association between acetaminophen use during pregnancy and neurodevelopmental conditions in children. While these studies do not definitively prove causation, plaintiffs argue that the findings were strong enough to require clearer warning labels so that expectant mothers could make informed decisions about pain and fever management.

Manufacturers dispute these allegations and maintain that acetaminophen is safe when used as directed. They also point to conflicting scientific evidence and regulatory guidance supporting its use during pregnancy. The litigation remains ongoing, with courts closely examining both the scientific evidence and the legal standards for failure to warn claims.

Why Tylenol Use During Pregnancy Is Under Legal Scrutiny

Tylenol use during pregnancy is under legal scrutiny because of claims that its active ingredient, acetaminophen, may pose risks to fetal brain development when taken by expectant mothers. Lawsuits allege that drug manufacturers failed to provide adequate warnings about a possible link between prenatal acetaminophen exposure and neurodevelopmental conditions such as autism and attention-deficit hyperactivity disorder. Plaintiffs argue that pregnant women were led to believe the medication was completely safe, despite emerging research suggesting potential concerns.

The legal focus has intensified due to several observational studies that found associations between acetaminophen use during pregnancy and developmental issues in children. Although these studies do not establish direct causation, they raised enough concern for plaintiffs to argue that stronger warnings were necessary. According to these claims, even a possible risk should have been clearly disclosed so that patients and doctors could weigh benefits against potential harms.

Drug manufacturers dispute these allegations and maintain that acetaminophen has long been considered the safest option for pain and fever relief during pregnancy when used as directed. Courts are now tasked with evaluating whether the available scientific evidence was sufficient to trigger a legal duty to warn, making the issue a matter of ongoing judicial review.

What Scientific Studies and Research Say About Acetaminophen and Autism

Scientific research on acetaminophen and autism has largely focused on observational studies examining medication use during pregnancy and later developmental outcomes in children. Some studies have reported an association between prenatal acetaminophen exposure and a higher incidence of autism spectrum disorder or attention deficit hyperactivity disorder. These findings are based on population data and parental reports, which have raised questions about whether prolonged or frequent use during pregnancy could influence fetal brain development.

However, researchers consistently note that these studies do not establish a direct cause and effect relationship. Observational research can be affected by confounding factors such as genetics, underlying maternal health conditions, infections, fever, or environmental influences that may independently increase autism risk. Many scientists caution that it is difficult to separate the effects of the medication itself from the reasons it was taken during pregnancy.

Large reviews and expert analyses have found the overall evidence to be mixed and inconclusive. Most health authorities continue to state that acetaminophen is generally considered safe for use during pregnancy when taken as directed. Ongoing research aims to better clarify potential risks while balancing the known dangers of untreated pain or fever during pregnancy.

What Health Risks Are Alleged — Autism, ADHD, and Neurodevelopmental Disorders

The Tylenol autism litigation raises concerns about whether acetaminophen use during pregnancy may affect a child’s developing brain. Plaintiffs claim that exposure during critical stages of fetal development could increase the risk of certain behavioral and cognitive conditions. These allegations are based on scientific studies that observed associations between prenatal acetaminophen use and developmental outcomes, leading to claims that clearer warnings should have been provided to expectant mothers.

Below are the main health risks cited in these lawsuits, each linked to concerns about how prenatal exposure may influence neurological development.

Autism Spectrum Disorder

Autism spectrum disorder is a central focus of the lawsuits. Plaintiffs allege that acetaminophen exposure in the womb may increase the likelihood of autism related traits, such as difficulties with social interaction, communication, and repetitive behaviors. The claims rely on studies showing higher autism diagnosis rates among children whose mothers reported acetaminophen use during pregnancy, particularly with long term or frequent use. While causation has not been proven, these findings form the basis of the legal arguments.

Attention Deficit Hyperactivity Disorder

Attention deficit hyperactivity disorder is another condition frequently cited in the litigation. Research discussed in the claims suggests a possible association between prenatal acetaminophen exposure and increased risks of attention problems, hyperactivity, and impulsive behavior. Plaintiffs argue that these outcomes may reflect disruptions in brain development during pregnancy, especially when exposure occurs during sensitive developmental windows.

Other Neurodevelopmental Disorders

The lawsuits also reference broader neurodevelopmental concerns beyond autism and ADHD. These include potential impacts on learning ability, emotional control, and overall cognitive development. Plaintiffs suggest that acetaminophen could interfere with biological processes involved in brain growth, potentially leading to developmental delays. Manufacturers continue to dispute these allegations, stating that current evidence remains inconclusive.

Who Is Involved — Plaintiffs, Manufacturers, and Defendants

The Tylenol autism lawsuits involve multiple parties, each playing a distinct role in the litigation. At the center of these cases are families seeking answers and accountability, along with pharmaceutical companies and retailers accused of failing to warn consumers. Understanding who is involved helps clarify how these claims are structured and why the litigation has expanded across different courts.

Plaintiffs

The plaintiffs are primarily parents or guardians of children diagnosed with autism, ADHD, or other neurodevelopmental conditions. In most cases, the mothers report using Tylenol or other acetaminophen based medications during pregnancy, often relying on the belief that these products were safe for prenatal use. Plaintiffs allege that they would have limited or avoided acetaminophen use had they been properly warned about the potential risks, and they seek compensation for medical expenses, long term care, and other related damages.

Manufacturers

Manufacturers include the companies responsible for producing and marketing Tylenol and generic acetaminophen products. Plaintiffs argue that these companies had access to scientific research suggesting possible developmental risks but failed to update warning labels or adequately inform the public. The manufacturers deny these claims and maintain that acetaminophen is safe when used as directed.

Other Defendants

In addition to manufacturers, some lawsuits name major retailers and distributors that sold acetaminophen products. These defendants are accused of contributing to the alleged failure to warn by continuing to market and sell the products without additional risk disclosures.

What Allegations Have Been Made Against Tylenol Manufacturers

The allegations against Tylenol manufacturers focus on claims that they failed to act responsibly as evidence emerged about potential risks associated with acetaminophen use during pregnancy. Plaintiffs argue that the companies prioritized product sales over consumer safety by continuing to promote Tylenol as safe for pregnant women without adequately addressing possible neurodevelopmental concerns.

A central allegation is failure to warn. Lawsuits claim that manufacturers knew or should have known about studies suggesting a possible link between prenatal acetaminophen exposure and autism or ADHD but did not update product labels or provide clearer guidance. Plaintiffs contend that even if the risk was uncertain, manufacturers had a duty to inform consumers so they could make informed decisions during pregnancy.

Another key allegation involves misleading marketing. Plaintiffs argue that Tylenol was actively marketed as the safest pain relief option for expectant mothers, reinforcing a perception of complete safety. According to the lawsuits, this messaging discouraged alternative treatments or more cautious use, ultimately exposing unborn children to potential risks without proper disclosure. Manufacturers deny these allegations and maintain that existing scientific evidence does not support stronger warnings.

What Evidence Exists — Medical Studies, Internal Documents, and Expert Analysis

The Tylenol autism lawsuits rely on different categories of evidence to support claims that manufacturers failed to adequately warn consumers about potential risks. Plaintiffs argue that when viewed together, scientific research, company records, and expert opinions raise enough concern to justify stronger warnings. Defendants maintain that this evidence has been misinterpreted and does not meet the legal standard required to prove liability.

The following types of evidence are most commonly cited in these cases, each addressing a different aspect of the allegations.

Medical Studies

Medical research is the primary scientific basis for the lawsuits. Plaintiffs reference observational studies that reported associations between acetaminophen use during pregnancy and increased rates of autism, ADHD, and other neurodevelopmental conditions. These studies analyze population data to identify patterns between prenatal exposure and later developmental outcomes. Although they do not establish a direct cause and effect relationship, plaintiffs argue that the repeated findings across multiple studies should have prompted clearer warnings.

Internal Documents

Corporate records are used to address what manufacturers knew and when they knew it. Plaintiffs allege that internal documents, such as safety assessments or research discussions, show awareness of potential concerns related to prenatal acetaminophen exposure. According to the lawsuits, this information was not adequately reflected in product labeling or consumer guidance. Manufacturers respond that internal reviews consistently supported existing safety recommendations.

Expert Analysis

Expert opinions help interpret both the science and corporate conduct. Plaintiffs’ experts suggest that acetaminophen may affect biological pathways involved in fetal brain development, offering a plausible explanation for the observed associations. Defense experts counter that the available data remains inconclusive and does not prove causation.

Legal Framework — Mass Tort Litigation vs Individual Lawsuits

The Tylenol autism claims are being pursued under different legal approaches, depending on how plaintiffs choose to structure their cases. Understanding the legal framework helps explain why some claims are grouped together while others proceed independently. Each path has distinct procedures, advantages, and challenges for both plaintiffs and defendants.

There are two primary legal routes used in this litigation, each shaping how cases are handled and evaluated by the courts.

Mass Tort Litigation

Mass tort litigation allows many plaintiffs with similar allegations to pursue claims against the same defendants while keeping each case legally separate. In this framework, cases may be consolidated for pretrial purposes, such as evidence gathering and expert review, to improve efficiency and consistency. Each plaintiff must still prove individual facts, including medication use, injury, and damages. This approach is commonly used in large pharmaceutical cases where the alleged harm affects many people but in different ways.

Individual Lawsuits

Individual lawsuits are filed separately and proceed on their own timelines. This approach gives plaintiffs greater control over their cases and allows courts to consider the unique medical history and circumstances of each family. Individual cases may be preferred when facts differ significantly or when plaintiffs believe their damages warrant separate consideration. However, this route can be more time consuming and costly compared to coordinated mass tort proceedings.

Timeline of the Tylenol Autism Lawsuit

Let us check out the following timeline for the Tylenol autism lawsuit – 

September 22, 2025 – Trump Administration Comments on Autism and Acetaminophen

Reports indicate that the Trump administration intends to publicly address a potential link between acetaminophen and autism, recommending that pregnant women limit use unless treating a fever. A planned press conference promises to present what officials describe as new findings, though the impact on ongoing Tylenol lawsuits and the Second Circuit appeal remains uncertain.

September 10, 2025 – Second Circuit Prepares for Oral Arguments

The U.S. Court of Appeals for the Second Circuit had scheduled oral arguments for October 6 regarding multiple claims that prenatal Tylenol use may increase the risk of autism in children. These cases are part of the larger Tylenol multidistrict litigation, consolidating hundreds of similar claims. The appellate review is seen as a critical moment, addressing both scientific evidence and procedural questions that could determine whether the lawsuits proceed or are dismissed in federal court.

September 8, 2025 – Federal Autism Report Pending Release

The federal government has not yet begun drafting its anticipated report on autism, but FDA Commissioner Marty Makary indicated it should be issued within a month. While the report is expected to examine potential causes of autism, Makary suggested that prenatal Tylenol use may not be a central focus, downplaying speculation on its role.

September 5, 2025 – RFK Jr. Report on Tylenol Speculated

Kenvue stock fell over 10 percent following reports that HHS Secretary Robert F. Kennedy Jr. may soon release a report examining a possible link between acetaminophen use during pregnancy and autism. Media reports indicate the review could also explore folate-derived treatments for certain autism symptoms. While not conclusive, the report could reignite interest in the ongoing litigation.

August 26, 2025 – New Study Adds Momentum

A study from the Icahn School of Medicine at Mount Sinai reviewed 46 studies on prenatal acetaminophen exposure and found that most indicated an increased risk of autism, ADHD, or related neurodevelopmental conditions. Notably, the studies with stronger methodologies were the ones most likely to show a link. Evidence that acetaminophen crosses the placenta and may affect fetal brain development strengthens the scientific argument, even after the MDL judge previously excluded expert testimony. While this does not automatically reopen federal cases, the research could provide future plaintiffs a more rigorous basis to pursue claims in state courts or other forums, and may influence FDA labeling discussions.

February 22, 2025 – Biomarker Study Highlights ADHD Risk

A new study published in Nature Mental Health raised concerns about prenatal acetaminophen use. Researchers analyzed second-trimester blood samples from 307 mothers and found that children exposed in utero were over three times more likely to develop ADHD. The effect was particularly notable in girls, who were six times more likely to be affected. Investigators recommended revisiting safety guidelines for acetaminophen during pregnancy.

January 3, 2025 – Oral Arguments in the Second Circuit

The U.S. Court of Appeals for the Second Circuit held oral arguments regarding the ongoing appeal. The hearing allowed both sides to present their positions as the appeal challenges the district court’s exclusion of plaintiffs’ expert testimony and the dismissal of the multidistrict litigation. The outcome is expected to shape the future course of these cases.

September 29, 2024 – Plaintiffs Challenge MDL Ruling

In their appellate brief, plaintiffs contend that Judge Cote overstepped by effectively resolving a complex scientific dispute herself, rather than allowing a jury to weigh the evidence. They argue that the district court improperly excluded all five general causation experts under Rule 702(d), applying novel and unsubstantiated standards to distinguished scientists such as Drs. Andrea Baccarelli, Eric Hollander, and Brandon Pearson.

Plaintiffs assert that the judge disregarded established scientific methods, including the Bradford Hill criteria, which Dr. Baccarelli used to evaluate potential links between prenatal acetaminophen exposure and autism or ADHD. They maintain that the ruling emphasized public policy concerns over methodological reliability, effectively positioning the court as a scientific arbiter. The Second Circuit’s decision on the appeal is anticipated in early 2025 and may significantly influence the trajectory of the litigation.

Questions remain about the next steps in the Tylenol autism lawsuits. Observers compare the situation to the Zantac litigation, where plaintiffs initially struggled in the MDL but later found limited success in state courts. While an appeal of Judge Cote’s ruling is pending, there has been no rush to file new Tylenol claims in state courts.

Several pre-existing state court cases continue to move forward:

• Bartle Case (St. Clair County, Illinois): Motion to dismiss based on preemption under advisement, with a hearing on September 30, 2024.
• Cooksey Case (Madison County, Illinois): Motions to dismiss fully briefed, hearing scheduled for October 30, 2024.
• Davey Case (Alameda County, California): Trial set for April 11, 2025, with discovery ongoing.
• Fennewald Case (Cook County, Illinois): Motions to dismiss pending, hearing on October 3, 2024.
• Bellmon Case (St. Clair County, Illinois): Motions to dismiss filed June 27, 2024, currently under briefing.

August 22, 2024 – Federal Litigation Concludes

Judge Cote granted summary judgment, effectively ending the federal MDL unless plaintiffs succeed on appeal. This ruling closes the federal avenue for most claims, shifting attention to state courts and ongoing appeals.

July 15, 2024 – Plaintiffs’ Expert Testimony Rejected

Earlier optimism about Dr. Roberta Ness testifying for plaintiffs proved unfounded. Judge Cote deemed her causation opinion inadmissible, citing gaps in her expertise in psychiatry, toxicology, and neurology, as well as methodological weaknesses. The ruling emphasized recent NIH research showing no significant link between acetaminophen and ADHD after adjusting for genetic factors, and criticized selective use of evidence. Following this, defendants moved for summary judgment, which was subsequently granted.

June 6, 2024 – Renewed Hope for the MDL with Dr. Ness

Following last year’s exclusion of all plaintiffs’ experts due to methodological shortcomings, plaintiffs returned to court with a highly qualified new expert, Dr. Roberta Ness. She addressed prior concerns by focusing specifically on ADHD, relying on diagnostic studies rather than symptom-based analyses, accounting for genetic confounders, and critically evaluating opposing organizational opinions.

Dr. Ness also tackled dose-response relationships and biological plausibility, citing peer-reviewed literature to support her methodology. While defense counsel challenged her testimony, their arguments faced stiffer scrutiny this time. Observers note renewed optimism that her testimony may satisfy Daubert standards and bolster the MDL’s viability.

May 28, 2024 – Dr. Ness Becomes Plaintiffs’ Key MDL Expert

Dr. Ness was deposed as the central expert in the MDL, presenting her analysis that acetaminophen could contribute to ADHD and autism. Using the Bradford Hill criteria—a widely accepted framework for establishing causation in epidemiology—she evaluated strength, consistency, temporality, and biological plausibility among other factors.

Her analysis initially covered both ADHD and autism prior to her formal retention, later focusing specifically on ADHD after Judge Cote’s Daubert ruling. She explained overlaps between ADHD and autism to justify including relevant studies, addressing a key reason prior experts were excluded. While the defense highlighted minor issues unrelated to causation, her deposition demonstrated rigorous methodology and adherence to scientific standards, positioning her testimony as a strong contender for admissibility.

March 18, 2024 – Another Chance in the MDL

Following the Daubert ruling, plaintiffs introduced a new expert to strengthen their claims. Defendants were given a deadline in July to file a motion to exclude this expert, with a determination expected in late summer or early fall. At this stage, no new Tylenol cases are being accepted, as attention remains focused on the ongoing litigation and related baby food autism lawsuits for children under six.

February 17, 2024 – Judge Open to New Expert Testimony

Judge Cote signaled willingness to consider testimony from Dr. Roberta Ness, who links prenatal acetaminophen exposure to ADHD. Both sides were instructed to propose a briefing schedule to assess the admissibility of her analysis. While defendants criticized her work as flawed, plaintiffs argued that new cases should not be constrained by prior rulings affecting earlier participants in the MDL.

February 3, 2024 – Plaintiffs Challenge Exclusion of Experts

A group of twelve families filed motions seeking to present their own expert testimony after previous MDL rulings disqualified experts supporting similar claims. They argued that their cases should be evaluated on individual merit, citing Third Circuit precedent emphasizing plaintiffs’ right to have unique evidence considered despite prior exclusions.

January 18, 2024 – Facing Potential Dismissal

Plaintiffs in the MDL were required to provide justification by February 1 to prevent dismissal of cases filed via Short Form Complaints issued on or before January 11, 2024. This affected approximately 501 plaintiffs who had formally joined the MDL, though it did not impact other potential plaintiffs who had yet to engage counsel or join the litigation.

January 15, 2024 – Exploring Alternative Paths for Compensation

Following Judge Cote’s ruling, the 501 plaintiffs in the MDL plan to appeal. Meanwhile, other families are evaluating state court options. Plaintiffs’ attorneys are actively discussing strategies for pursuing claims outside federal court, including which jurisdictions may offer the best opportunity for their cases.

January 8, 2024 – Court-Ordered Conference

Judge Cote directed both parties to meet and submit a joint letter by January 12 outlining proposed next steps after her recent decision. With the MDL effectively stalled, this conference mainly formalized procedural matters and did not produce significant developments.

January 1, 2024 – Analysis of Judge Cote’s Ruling

The court’s ruling effectively ended the federal MDL for Tylenol autism claims. Detailed analysis shows that the judge found the plaintiffs’ scientific experts lacked reliable methodology and could not credibly link prenatal acetaminophen exposure to autism, ADHD, or related conditions.

December 19, 2023 – MDL Ruling and Implications for Baby Food Lawsuits

Judge Cote’s 148-page Daubert ruling rejected the plaintiffs’ expert testimony, concluding that the scientific evidence did not reliably demonstrate causation. While this was a major setback for the federal MDL, lawyers note potential opportunities in state court, particularly in Pennsylvania, New Jersey, and California, and families with young children may still have avenues for claims.

December 8, 2023 – Market Reaction to Daubert Hearing

Kenvue Inc., recently spun off from Johnson & Johnson, saw its stock rise roughly 10 percent following the Daubert hearing, reflecting investor confidence that the outcome favored the defendants.

December 7, 2023 – Daubert Hearing Observations

The Daubert hearing concluded in New York, though our firm did not attend. Early reports indicate that plaintiffs faced challenges presenting their evidence. While judges’ reasoning can be unpredictable, initial impressions suggest the plaintiffs’ chances in federal court were diminished, signaling a difficult path ahead for the MDL.

December 4, 2023 – Settlement Conference Scheduled

A settlement scheduling conference is set for Thursday, January 4, 2024. While some speculated it could provide hints regarding the Daubert ruling, outcomes remain uncertain, and any predictions are purely speculative.

December 1, 2023 – Awaiting Key Hearing

All parties are awaiting the upcoming hearing, expected to be a pivotal moment for the Tylenol autism litigation. The decision could significantly impact the trajectory of the MDL and future filings.

November 17, 2023 – MDL Expands with 58 New Cases

Fifty-eight additional cases were added to the Tylenol autism MDL, bringing the total to 441. If Judge Cote overrules defendants’ Daubert challenges, the number of active claims could increase further, intensifying the litigation.

November 11, 2023 – Daubert Hearing Scheduled for December 7

The court announced a Daubert hearing on December 7, 2023, which will proceed without live expert testimony. While the absence of witnesses makes predicting outcomes difficult, there remained cautious optimism that plaintiffs’ submissions might withstand scrutiny.

November 8, 2023 – State Court Tylenol Cases Progress

Several acetaminophen lawsuits are moving forward in state courts, including one in Madison County, Illinois. Briefing schedules have been established, with plaintiff responses due by December 12, 2023, and defendant replies by January 12, 2024. A hearing is expected in early 2024. Should federal MDL cases fail under Daubert, attention may shift to these state proceedings.

November 3, 2023 – Possible Quick Win on Daubert

All briefs were submitted in preparation for the Daubert challenge, with a hearing potentially the week of December 5, 2023. Plaintiffs hoped for a favorable ruling based on the written submissions alone, with any hearing expected to be brief and focused on targeted legal questions.

November 1, 2023 – All Daubert Briefs Filed

All parties have submitted their Daubert briefs to Judge Cote, addressing which expert testimony will be admissible. Each expert had separate briefs across three rounds, totaling several thousand pages including supporting exhibits. The next step is for the court to hold hearings to consider these motions and potentially hear from select experts directly.

October 17, 2023 – MDL Surpasses 380 Cases

The Tylenol autism MDL continues to expand, with 111 new cases added last month, bringing the total to 382. After an initially slow start of fewer than 20 cases per month, filings have steadily increased, signaling growing engagement by plaintiffs’ attorneys.

October 9, 2023 – Proposals for Daubert Hearing Logistics

Judge Cote requested proposals on the structure of the upcoming Daubert hearings. Defendants pushed for an extended week-long hearing to fully contest the scientific evidence, while plaintiffs advocated for a shorter process, suggesting the judge pre-identify which experts need to be heard to streamline proceedings.

October 5, 2023 – Defense Objects to Supplemental Expert Reports

Defendants challenged plaintiffs’ plan to submit supplemental reports incorporating a recent study, citing Rule 26 and arguing the pre-print nature of the study makes it untimely. Observers noted the objection may reflect either strategic caution or an attempt to limit new evidence.

October 4, 2023 – New Study Examines Acetaminophen and Fetal Brain Development

A recent lab study exposed cells mimicking early human brain development to acetaminophen at levels comparable to typical prenatal use. Results suggest possible impacts on genes controlling brain growth and neural communication, aligning with genetic findings in children exposed in utero. Plaintiffs are updating expert reports in response to this research ahead of Daubert hearings.

October 2, 2023 – Revisions to Plaintiff Fact Sheets Completed

The parties notified Judge Cote that revisions to Plaintiff Fact Sheets and health records authorization forms are complete. These changes aim to streamline information collection for new plaintiffs and address logistical challenges in the MDL.

September 23, 2023 – Motion to Exclude Defense Experts

Plaintiffs filed motions seeking to exclude certain defense experts ahead of the Daubert hearing, citing various procedural and substantive reasons to challenge their testimony.

September 22, 2023 – Plaintiffs’ Expert Team Announced

The Tylenol MDL for autism claims features five general causation experts for the plaintiffs:

• Dr. Andrea Baccarelli, MD, PhD – Chair of the Department of Environmental Health Sciences at Columbia University, Dr. Baccarelli specializes in the chemical and molecular links between human disease and exposure to drugs or chemicals. He has published over 600 articles, is a member of the National Academy of Medicine, and serves as President of the International Society of Environmental Epidemiology.
• Dr. Robert Cabrera, PhD – Associate Professor at Baylor College of Medicine, Dr. Cabrera is a molecular and cellular biologist focusing on chemical causes of birth defects during embryonic development.
• Dr. Eric Hollander, MD – Professor of Psychiatry at Albert Einstein College of Medicine, Dr. Hollander has led numerous federal studies on autism causes, funded by the FDA and NIH. He has published hundreds of articles and edited multiple textbooks on Autism Spectrum Disorders.
• Dr. Stan G. Louie – Professor of Clinical Pharmacy at the University of Southern California, Dr. Louie researches drug development for inflammatory, cancer, and neurodegenerative diseases.
• Dr. Brandon Pearson, PhD – Assistant Professor of Environmental Health Sciences at Columbia University, Dr. Pearson is a neuroscientist and toxicologist specializing in neurotoxicology, epigenetics, and environmental causes of autism. Though new to litigation, he volunteered his expertise for this case.

These experts collectively bring substantial scientific and clinical credentials to the litigation.

September 18, 2023 – MDL Doubles in Size Over Summer

The Tylenol autism MDL nearly doubled over the summer, growing from 136 to 265 pending cases. While this seems significant, it represents only a fraction of the broader pool, as over 100,000 Tylenol-related claims remain on hold pending Judge Cote’s determination on whether they can proceed.

September 12, 2023 – Court Denies Hearing Request

Following an FDA statement, defendants requested a status conference to argue for dismissal of the MDL. Judge Cote swiftly rejected this request within two hours, reaffirming that the Daubert deadlines and procedural schedule would remain unchanged. The court emphasized that the FDA’s stance does not automatically determine the outcome of the litigation.

September 8, 2023 – FDA Declines to Intervene

The FDA formally declined the court’s invitation to submit a statement of interest in the Tylenol autism litigation. The agency noted that current observational studies on acetaminophen and neurobehavioral or urogenital outcomes are limited and inconsistent, preventing a determination of causality. The FDA emphasized that it does not participate in third-party litigation, while continuing to monitor product safety through administrative channels. Plaintiffs viewed this non-involvement as a favorable development for their cases.

September 1, 2023 – Court Seeks FDA Input on Warnings

In April, Judge Cote requested the FDA’s assessment regarding proposed warnings for acetaminophen labels, specifically whether existing scientific evidence justifies advising pregnant women of potential autism or ADHD risks. The FDA requested additional time, extending the deadline to September 15. The agency’s response—or lack thereof—was expected to influence the upcoming Daubert motions, which focus on the admissibility of plaintiffs’ scientific evidence.

August 24, 2023 – Tylenol Litigation Status Update

Depositions of expert witnesses were ongoing, focusing on whether prenatal acetaminophen exposure could cause autism or ADHD. Plaintiffs remained confident in the strength of their scientific evidence, anticipating favorable Daubert rulings or, at minimum, viable claims in state courts. Even if trials proceeded, potential verdicts were expected to reach multimillion-dollar levels.

August 21, 2023 – Judge Approves Consolidated Daubert Briefs

Judge Cote permitted defendants to file a consolidated brief addressing Daubert challenges to plaintiffs’ expert testimony. Plaintiffs had requested separate briefs for each expert to ensure fairness. The outcome of these Daubert rulings would be pivotal: exclusion of the causation evidence could lead to dismissal of all pending federal MDL cases.

August 14, 2023 – Negligent Misrepresentation Claims Barred in Certain States

In a joint filing to Judge Cote, both plaintiffs and defendants agreed that negligent misrepresentation claims based on omissions cannot be pursued in several states, including Arkansas, California, Colorado, Idaho, Indiana, Kentucky, Nebraska, New Hampshire, North Carolina, North Dakota, Ohio, South Dakota, Tennessee, Texas, and Wyoming. While this limits some legal avenues, it is not expected to materially affect the overall outcome of the Tylenol autism cases.

August 4, 2023 – Daubert Motions Scheduled

The future of the MDL largely hinges on Judge Cote’s rulings on Daubert motions, which determine the admissibility of expert testimony. Both parties are required to submit motions by September 19, 2023, along with letters recommending the sequence of reviewing exclusion motions and which overlapping expert arguments should be considered together.

August 1, 2023 – FDA to Provide Input on Warning Labels

Judge Cote requested a statement of interest from the FDA regarding proposed warning labels for acetaminophen, focusing on pregnancy-related risks. The government received an extension to submit its opinion, allowing the parties to review the statement just before filing their initial Daubert motions due September 19, 2023.

July 18, 2023 – MDL Experiences Highest Filing Volume to Date

Over the past month, 64 new cases were added to the Tylenol autism MDL in the Southern District of New York, marking the highest monthly filing volume since the MDL’s creation. The MDL now contains approximately 200 pending pregnancy-related claims, while thousands of potential plaintiffs remain on hold, awaiting the outcome of upcoming evidentiary rulings.

July 10, 2023 – Many Plaintiffs Remain on the Sidelines

Despite being consolidated for over six months, the MDL had fewer than 150 pending Tylenol autism or ADHD lawsuits. Legal experts attribute this to tens of thousands of prospective plaintiffs waiting to see the results of Daubert challenges before deciding whether to proceed in federal court or pursue state court claims. Some filings continue for statute of limitations reasons, but the majority remain in a holding pattern.

July 1, 2023 – Ongoing State Court Tylenol Lawsuits

Several acetaminophen lawsuits are also progressing in state courts. For example, an Illinois mother filed a claim against Walgreen Co. on behalf of her daughter. Because both parties are Illinois residents, the case cannot be brought in federal MDL due to lack of diversity jurisdiction.

June 5, 2023 – Plaintiffs Oppose J&J’s Immediate Appeal Request

Johnson & Johnson sought an immediate appeal of the court’s preemption and causation rulings, which could have delayed the MDL for up to a year. Plaintiffs filed a motion opposing this request, arguing that immediate appeal is an uncommon exception and that the Daubert hearing scheduled later in the year will properly address the causation issues.

May 22, 2023 – Texas Tylenol Lawsuits Dismissed, California Claims Continue

The MDL judge granted a motion to dismiss a Tylenol autism case involving CVS and other retail defendants under Texas’s “safe harbor” law. This statute shields retailers from liability if FDA-approved labeling was followed, meaning Texas-based Tylenol claims could be dismissed. In contrast, a similar California case was allowed to proceed, and plaintiffs can still pursue claims under California law.

May 17, 2023 – Target and Walmart Must Defend Against Claims

Retailers Target Corp. and Walmart Inc. were required to defend lawsuits alleging their store-brand acetaminophen failed to warn of autism or ADHD risks from prenatal use. Judge Cote rejected their preemption argument, ruling that compliance with federal law does not automatically shield them under state law. The claims for California plaintiffs remain valid, while Texas-based claims face dismissal.

May 9, 2023 – Johnson & Johnson Requests Immediate Appeal

Johnson & Johnson sought an interlocutory appeal of Judge Cote’s rejection of their preemption motion, aiming to obtain appellate review before the case progresses. Such appeals are rare and typically only allowed in exceptional circumstances. Approval was considered unlikely, as it could delay ongoing litigation that the court intended to advance.

May 1, 2023 – Court Seeks FDA’s Opinion on Labeling

In an unusual move, Judge Cote requested the FDA’s input on whether a warning regarding prenatal acetaminophen use should be added to product labels. The court asked whether the plaintiffs’ proposed warning is warranted and if current science supports advising pregnant women about potential risks of autism or ADHD. Such direct requests to the FDA are rare and highlight the significance of this mass tort litigation.

April 21, 2023 – Judge Denies Johnson & Johnson’s Preemption Motion

Judge Cote rejected J&J’s motion to dismiss the lawsuit based on federal preemption. The company had argued that federal law and FDA regulations prevented them from adding a warning about potential autism or ADHD risks. The judge concluded that federal rules did not bar J&J from including such warnings, echoing a prior decision denying Walmart’s preemption claim.

April 21, 2023 – Judge Denies Johnson & Johnson’s Preemption Motion

Judge Cote issued an order rejecting J&J’s request to dismiss the Tylenol autism lawsuit based on the preemption doctrine. The company argued that federal law and FDA regulations barred claims that it failed to warn about potential prenatal risks. The judge concluded that nothing in federal rules prevented J&J from providing a warning about in utero exposure, echoing her prior decision denying a similar motion by Walmart.

April 20, 2023 – Judge Seeks Government Input on Proposed Tylenol Warning Labels

In a rare procedural move, the court asked the federal government to provide its perspective on the plaintiffs’ proposed warning regarding autism and ADHD risks from prenatal acetaminophen use. While current labeling only includes a general pregnancy warning, the judge is exploring whether additional advisories should be added. Any FDA opinion would guide the court but is advisory rather than legally binding.

April 13, 2023 – Proposed Warning Text for Autism and ADHD Risks

Plaintiffs suggested a label reading: “Some studies show that frequent use of this product during pregnancy may increase your child’s risk of autism and attention deficit hyperactivity disorder. Use the lowest effective dose for the shortest possible time and at the lowest possible frequency.” This proposed text aims to ensure that pregnant women receive scientifically informed guidance when using acetaminophen.

March 31, 2023 – Expert Discovery Order Issued

The MDL court issued guidance regarding expert testimony in the acetaminophen-ASD/ADHD litigation. The judge ruled that rebuttal expert testimony must adhere to the established expert discovery schedule, despite objections from defendants. Plaintiffs had until March 15 to indicate whether they would designate an expert in maternal-fetal medicine. On March 17, they informed defendants they would not submit an affirmative report but reserved the right to offer a rebuttal report. The court clarified that plaintiffs may only submit a rebuttal report if they first serve an affirmative report and must disclose their decision by April 4.

The broader takeaway: although plaintiffs do not anticipate needing a maternal-fetal medicine expert for general causation, reserving a rebuttal expert is prudent in anticipation of defense arguments. Overall, this MDL continues to move at a rapid pace.

February 11, 2023 – Submission of Plaintiffs’ Fact Sheets

Both parties are required to submit joint or competing plaintiffs’ fact sheets by February 28, 2023. These fact sheets capture essential details about each plaintiff, including personal information, injuries, defendants involved, and the legal theories being asserted. Beyond administrative purposes, fact sheets help identify common issues, patterns, and potential bellwether trial candidates, providing insight into the broader scope of the litigation and assisting in settlement planning.

Read about the OGX Lawsuit Updates

January 11, 2023 – Short Form Complaint Approved

Judge Denise Cote approved a Short Form Complaint for incoming plaintiffs in the Tylenol autism MDL. This streamlined filing process allows new plaintiffs to reference allegations in the master complaint without repeating the full list of claims, making it easier and faster to join the litigation. Combined with the ability to directly file cases in the MDL, this procedural change is expected to accelerate new filings significantly.

January 9, 2023 – New Tylenol Autism Lawsuit Transferred to MDL

A recent case, Smith v. Walmart (0:22-cv-62092), originally filed in Florida, has been transferred to the New York MDL. The lawsuit involves a mother and child alleging that prenatal use of Walmart’s Equate acetaminophen led to the child developing autism. All federal Tylenol autism cases filed across the country, including California, Pennsylvania, and Ohio, are similarly consolidated in New York for streamlined litigation management.

January 1, 2023 – Appointment of Special Master

Randi Ellis has been appointed Census Special Master in the Tylenol autism MDL. She will oversee the coordinated collection and organization of key information from all plaintiffs, ensuring that the data is usable by both the parties and the court. Ms. Ellis brings extensive experience to the role, having served as Special Master in multiple MDLs in 2022.

December 13, 2022 – Tylenol Class Action Progresses Quickly

The MDL judge is requiring plaintiffs to file a master complaint by the end of the week, which will govern all future actions in the litigation. A Short Form Complaint for new cases will be jointly submitted by January 4, 2023. The judge has moved rapidly on multiple motions, setting tight deadlines—sometimes as short as two weeks—for substantial matters including electronic discovery, confidentiality protections, and master complaint procedures. This proactive approach aims to accelerate resolution and potential settlements for victims.

November 20, 2022 – Types of Cases Included in the MDL

While autism and ADHD remain the primary focus, the law firm is considering claims involving other neurodevelopmental disorders, including:

• Asperger’s Syndrome
• Kanner’s Syndrome
• Childhood Disintegrative Disorder
• Pervasive Developmental Disorder

November 15, 2022 – Walmart’s Motion to Dismiss Denied

Judge Denise Cote denied Walmart’s motion to dismiss the Tylenol autism claims based on federal preemption, issuing her ruling just two months after the motion was filed—an unusually fast turnaround for MDL litigation. The court held that FDA labeling regulations did not prevent Walmart from voluntarily adding pregnancy warnings to its Equate-brand acetaminophen. Judge Cote emphasized that manufacturers retain a duty to strengthen warnings when necessary. While expected, the ruling generated significant momentum for plaintiffs.

November 14, 2022 – Walmart Files Motion to Dismiss

Walmart moved to dismiss Tylenol autism claims, arguing that federal law preempted failure-to-warn allegations because acetaminophen labels are regulated by the FDA. Plaintiffs countered that FDA regulations permit manufacturers to voluntarily enhance warnings, including pregnancy-related risks. Walmart later filed a supplemental brief in support of its motion. Federal preemption is a common defense in pharmaceutical litigation, but it is rarely successful in failure-to-warn cases.

Read about the Hair Relaxer Lawsuit Updates

November 13, 2022 – Initial Status Conference in Tylenol MDL

Judge Denise Cote scheduled the first major status conference in the Tylenol autism MDL for November 17, 2022. Key agenda items included the appointment of the plaintiffs’ leadership committee and early case management planning. The conference was viewed as an important indicator of how aggressively the court intended to manage the litigation and move cases toward resolution.

November 7, 2022 – Defense Leadership Selected for Tylenol MDL

Judge Denise Cote approved the structure of the defense leadership committee in the Tylenol autism MDL. The committee, known as the Retailer Liaison Committee (RLC), will coordinate strategy and make collective decisions on behalf of the retailer defendants. Members of the RLC were chosen through an open application process, with formal appointments expected to be announced the following week.

November 4, 2022 – Tylenol Retail Defendants Announce $13 Billion Opioid Settlement

CVS, Walmart, and Walgreens—key defendants in the Tylenol autism litigation—announced a proposed $13 billion settlement to resolve thousands of unrelated opioid lawsuits brought by state and local governments. While separate from the acetaminophen cases, the settlement highlights the financial exposure of these retailers and provides context for why they are also targeted in large-scale product liability litigation.

October 5, 2022 – Tylenol Autism MDL Officially Created

The Judicial Panel on Multidistrict Litigation created a new MDL titled In re: Acetaminophen – ASD/ADHD, MDL No. 3043, assigning it to Judge Denise L. Cote in the Southern District of New York. More than 80 pending acetaminophen autism lawsuits were ordered transferred immediately. This marks Judge Cote’s ninth MDL appointment.

September 30, 2022 – JPML Hears Arguments on MDL Consolidation

The JPML heard oral arguments on whether to consolidate the growing number of acetaminophen autism lawsuits into a single MDL. Plaintiffs argued consolidation was necessary due to common factual and scientific issues, while manufacturers and retailers opposed the request. During the hearing, JPML Judge Matthew Kennelly remarked that the litigation could become “really gigantic,” underscoring the scale of the potential mass tort.

September 11, 2022 – JPML Sets Oral Arguments on MDL Consolidation

The Judicial Panel on Multidistrict Litigation scheduled oral arguments for September 29, 2022, in St. Louis on the motion to consolidate acetaminophen autism lawsuits into a single MDL class action. While several defendants oppose consolidation, plaintiffs’ counsel believes the legal standards for creating an MDL are met. The primary uncertainty at this stage is venue selection, with plaintiffs advocating for the Northern District of California and defendants favoring New Jersey.

August 9, 2022 – Plaintiffs Push Back Against MDL Opposition

Plaintiffs filed a Reply in Support of their motion to consolidate Tylenol autism lawsuits into a new MDL. The reply challenges defendants’ arguments against consolidation, asserting that the number of pending and anticipated cases easily satisfies MDL requirements. Plaintiffs also reaffirmed their position that the Northern District of California is the most appropriate and efficient forum for centralized proceedings.

August 2, 2022 – Defendants File Opposition to MDL Request

Defendants submitted multiple briefs opposing consolidation of the Tylenol autism lawsuits into an MDL. Although filed separately, the briefs raise similar objections. Defendants argue that lawsuits have been improperly limited to retailers rather than manufacturers, that the total number of cases is insufficient to justify consolidation, and that the proposed venues are inappropriate. They contend that, if an MDL is created, New Jersey or the Eastern District of New York would be more suitable locations.

Read about the Paragard IUD Lawsuit Updates

Current Status of the Litigation and Key Court Developments

The Tylenol autism litigation is still evolving, with courts closely examining both the legal and scientific foundations of the claims. While thousands of families have expressed interest in pursuing lawsuits, judges have focused on whether the available medical evidence meets the standards required to move these cases forward. As a result, recent developments have significantly shaped the direction and scope of the litigation.

Several key court actions define the current stage of these lawsuits and explain where the claims stand today.

Federal Court Developments

In federal court, many Tylenol autism cases were consolidated for coordinated review. Judges closely scrutinized expert testimony offered by plaintiffs, particularly on the issue of whether acetaminophen can be proven to cause autism or ADHD. Some federal claims were dismissed after courts ruled that the proposed expert opinions did not meet the required legal standards for scientific reliability. Appeals and procedural challenges have followed, keeping federal litigation active but limited in scope.

State Court Proceedings

After federal setbacks, many plaintiffs shifted their focus to state courts. State level cases may apply different evidentiary rules, allowing some claims to proceed that were dismissed federally. These cases are moving forward on individual timelines, with courts continuing to evaluate failure to warn allegations and the strength of supporting evidence. Overall, the litigation remains ongoing, with outcomes likely to vary by jurisdiction.

What Plaintiffs Are Seeking — Compensation, Medical Costs, and Accountability

Families who have filed Tylenol autism lawsuits are seeking both financial relief and accountability from the companies involved. Plaintiffs argue that the alleged failure to warn caused long term harm to their children and placed significant emotional and financial burdens on their families. Their claims focus not only on covering past losses but also on addressing future needs.

The following forms of relief are commonly requested in these lawsuits, each reflecting a different aspect of the alleged harm.

Compensation for Damages

Plaintiffs are seeking compensation for a wide range of damages related to their children’s diagnoses. This includes pain and suffering, emotional distress, and loss of quality of life. Families argue that the challenges associated with autism or ADHD affect daily functioning and long term independence, justifying substantial compensation.

Medical and Long Term Care Costs

Medical expenses are a major component of these claims. Plaintiffs seek reimbursement for past and ongoing costs such as doctor visits, diagnostic evaluations, therapy, behavioral treatment, and specialized educational services. Many families also request compensation for future care, as neurodevelopmental conditions often require lifelong support.

Corporate Accountability

Beyond financial recovery, plaintiffs seek accountability from manufacturers and sellers. Lawsuits aim to hold companies responsible for alleged failures to warn and to encourage changes in labeling or marketing practices. For many families, accountability is viewed as a way to prevent similar harm to others in the future.

Read about the Paraquat Parkinson’s Lawsuit Claims

Who May Be Eligible to File a Tylenol Autism Claim

Eligibility to file a Tylenol autism claim generally depends on a combination of medical history, product use, and legal factors. These lawsuits are typically brought by families who believe prenatal exposure to acetaminophen contributed to a child’s developmental diagnosis. While eligibility standards can vary by jurisdiction, common criteria are often considered.

The following groups are most commonly identified as potential claimants in this litigation.

Parents or Legal Guardians of Affected Children

Parents or legal guardians of children diagnosed with autism, ADHD, or related neurodevelopmental disorders may be eligible to file a claim. In most cases, the mother reports using Tylenol or another acetaminophen based medication during pregnancy, either regularly or over an extended period. Plaintiffs generally allege that they were unaware of any potential risks at the time of use.

Individuals With Documented Prenatal Exposure

Claims often require some form of documentation showing acetaminophen use during pregnancy. This may include medical records, pharmacy receipts, or physician recommendations. Establishing prenatal exposure is a key factor in determining eligibility and strengthening a claim.

Families Within Legal Time Limits

Eligibility also depends on meeting statute of limitations requirements, which vary by state. These deadlines often begin when parents first became aware of a possible link between acetaminophen use and their child’s diagnosis. Families who act within the applicable time frame may still be eligible to pursue legal action.

What Parents Should Know — Safety Guidance and Risk Awareness

Expectant parents need clear information about medication use during pregnancy, and acetaminophen has recently come under scrutiny due to potential links with neurodevelopmental conditions. Understanding both current medical recommendations and emerging research can help parents make informed decisions about pain and fever management.

Acetaminophen is widely considered the safest over-the-counter option for pregnant women when used as directed. Healthcare providers generally recommend taking the lowest effective dose for the shortest time needed and consulting a doctor before prolonged or frequent use.

At the same time, some studies suggest a possible association between prenatal acetaminophen exposure and conditions like autism or ADHD. While evidence is not conclusive, parents should be aware of these concerns and discuss risks and benefits with their healthcare providers to make informed choices for their child’s health.

Read about the Gardasil Lawsuit Updates and Claims

Possible Settlements and Future Legal Outlook

The Tylenol autism litigation is ongoing, and the potential outcomes remain uncertain as cases continue through both federal and state courts. Settlements, if they occur, could provide compensation to affected families without requiring a full trial, but amounts will likely vary depending on the strength of individual claims, medical documentation, and jurisdiction.

Some plaintiffs may reach negotiated agreements with manufacturers to cover medical costs, therapy, and other damages related to their children’s neurodevelopmental conditions. In other instances, courts may allow cases to proceed to trial, particularly where claims involve strong evidence of prenatal acetaminophen exposure and resulting harm.

Looking ahead, the legal outlook depends on evolving scientific research and judicial interpretations of the evidence. Future developments could include broader mass tort consolidation, additional appeals, or changes in labeling practices. Families considering claims should stay informed about new rulings and legal updates.

Impact on Public Health Policy and Consumer Awareness

The Tylenol autism lawsuits have drawn attention to the importance of clear communication about medication safety during pregnancy. Even though scientific evidence remains inconclusive, the litigation has encouraged health authorities and medical professionals to review existing guidelines and emphasize informed decision-making for expectant parents.

Public health policy may be influenced by these claims through updated labeling recommendations or enhanced guidance for healthcare providers on discussing pain and fever management with pregnant patients. Authorities are increasingly focused on balancing the proven benefits of acetaminophen with the need for caution when used frequently or long term.

Consumer awareness has also grown as families seek to understand potential risks. Parents are now more likely to discuss medication use with doctors, carefully monitor dosage, and consider alternative approaches when appropriate. The lawsuits highlight how emerging research can shape both individual choices and broader public health messaging.

Read about the Transvaginal Mesh Lawsuit Updates

Conclusion — What This Lawsuit Means for Families Going Forward

The Tylenol autism litigation underscores the ongoing concerns about prenatal medication safety and the responsibilities of manufacturers to provide clear warnings. For families, the lawsuits highlight the importance of staying informed about potential risks, consulting healthcare providers, and documenting medical decisions during pregnancy.

While the scientific evidence linking acetaminophen to autism or other neurodevelopmental conditions remains inconclusive, the legal proceedings offer a pathway for affected families to seek compensation for medical costs, therapy, and long term care. Beyond financial relief, the cases aim to hold companies accountable and encourage safer labeling practices in the future.

Ultimately, this litigation emphasizes the need for vigilance, informed decision-making, and open communication with medical professionals. Families are better equipped to navigate choices about medication use during pregnancy and to advocate for the health and safety of their children.

FAQs on the Tylenol Autism Lawsuit